Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lerisetron. FAES.

Richard Huckle1

  • 1Axovan Ltd, Gewerbestrasse 16, 4123 Ailschwil, Switzerland. richard.huckle@axovan.com

Current Opinion in Investigational Drugs (London, England : 2000)
|November 19, 2003
PubMed
Summary

Lerisetron, a novel 5-hydroxytryptamine3 receptor antagonist, is being developed to combat chemotherapy-induced emesis. Clinical trials progressed through Phase II by 2001, advancing to Phase III development.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting.

Journal of neurodevelopmental disorders·2026
Same author

PBT-1 Prana Biotechnology.

Current opinion in investigational drugs (London, England : 2000)·2005
Same author

Gaboxadol. Lundbeck/Merck.

Current opinion in investigational drugs (London, England : 2000)·2004
Same author

Pregabalin (Pfizer).

Current opinion in investigational drugs (London, England : 2000)·2004

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Trials

Background:

  • Lerisetron is a 5-hydroxytryptamine3 receptor antagonist.
  • It is under development by FAES Farma.
  • The drug is intended for the potential treatment of emesis resulting from chemotherapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of lerisetron in treating chemotherapy-induced emesis.
  • To advance lerisetron through clinical trial phases.

Main Methods:

  • Phase I trials initiated in Spain in 1994.
  • Phase II trials conducted in the UK as of June 2000.
  • Phase II trials completed by the end of 2001.

Main Results:

  • Clinical trials progressed from Phase I to Phase III.
  • Phase II trials were successfully completed by end of 2001.

Conclusions:

  • Lerisetron development advanced to Phase III trials.
  • The compound shows potential for managing chemotherapy-induced emesis.